{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:18:14Z","timestamp":1789154294665,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51264-2","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T15:03:00Z","timestamp":1723215780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-580X","authenticated-orcid":false,"given":"Romain","family":"Gui\u00e8ze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-755X","authenticated-orcid":false,"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc-Mathieu","family":"Fornecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Ferrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Aurran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Clavert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"de Guibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Dr\u00e9nou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Quittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Hivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8923-6010","authenticated-orcid":false,"given":"Julie","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Quinquenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Broseus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Rouille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4246-5688","authenticated-orcid":false,"given":"Benoit","family":"Magnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Lazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"V\u00e9ron\u00e8se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"de Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"51264_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","volume":"29","author":"EM Parry","year":"2023","unstructured":"Parry, E. M. et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat. Med. 29, 158\u2013169 (2023).","journal-title":"Nat. Med."},{"key":"51264_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1182\/hematology.2022000345","volume":"2022","author":"PA Thompson","year":"2022","unstructured":"Thompson, P. A. & Siddiqi, T. Treatment of Richter\u2019s syndrome. Hematology 2022, 329\u2013336 (2022).","journal-title":"Hematology"},{"key":"51264_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.22.01028","volume":"41","author":"E Smyth","year":"2023","unstructured":"Smyth, E., Eyre, T. A. & Cheah, C. Y. Emerging therapies for the management of Richter transformation. J. Clin. Oncol. 41, 395\u2013409 (2023).","journal-title":"J. Clin. Oncol."},{"key":"51264_CR4","doi-asserted-by":"publisher","first-page":"E239","DOI":"10.1002\/ajh.23841","volume":"89","author":"P Langerbeins","year":"2014","unstructured":"Langerbeins, P. et al. Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation. Am. J. Hematol. 89, E239\u2013E243 (2014).","journal-title":"Am. J. Hematol."},{"key":"51264_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood.V128.22.60.60","volume":"128","author":"P Hillmen","year":"2016","unstructured":"Hillmen, P. et al. Acalabrutinib monotherapy in patients with Richter transformation from the Phase 1\/2 ACE-CL-001 clinical study. Blood 128, 60\u201360 (2016).","journal-title":"Blood"},{"key":"51264_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids, M. S. et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin Lymphoma. J. Clin. Oncol. 35, 826\u2013833 (2017).","journal-title":"J. Clin. Oncol."},{"key":"51264_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","volume":"100","author":"F Bouclet","year":"2021","unstructured":"Bouclet, F. et al. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Ann. Hematol. 100, 987\u2013993 (2021).","journal-title":"Ann. Hematol."},{"key":"51264_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood.2021011386","volume":"139","author":"MS Davids","year":"2022","unstructured":"Davids, M. S. et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood 139, 686\u2013689 (2022).","journal-title":"Blood"},{"key":"51264_CR9","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"A-M Tsimberidou","year":"2006","unstructured":"Tsimberidou, A.-M. et al. Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J. Clin. Oncol. 24, 2343\u20132351 (2006).","journal-title":"J. Clin. Oncol."},{"key":"51264_CR10","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","volume":"129","author":"W Ding","year":"2017","unstructured":"Ding, W. et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129, 3419\u20133427 (2017).","journal-title":"Blood"},{"key":"51264_CR11","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes, A. et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 6, e67\u2013e78 (2019).","journal-title":"Lancet Haematol."},{"key":"51264_CR12","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot, A. et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood 127, 1410\u20131416 (2016).","journal-title":"Blood"},{"key":"51264_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas, P. et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 133, 1205\u20131216 (2019).","journal-title":"Blood"},{"key":"51264_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","volume":"30","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf, O. et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat. Med. 30, 240\u2013248 (2024).","journal-title":"Nat. Med."},{"key":"51264_CR15","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1200\/JCO.24.00033","volume":"42","author":"AS Kittai","year":"2024","unstructured":"Kittai, A. S. et al. Anti-CD19 chimeric antigen receptor T-cell therapy for richter transformation: an international, multicenter, retrospective study. J. Clin. Oncol. 42, 2071\u20132079 (2024).","journal-title":"J. Clin. Oncol."},{"key":"51264_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir, T. et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N. Engl. J. Med. 390, 326\u2013337 (2024).","journal-title":"N. Engl. J. Med."},{"key":"51264_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/his.13024","volume":"69","author":"EJ Soilleux","year":"2016","unstructured":"Soilleux, E. J. et al. Diagnostic dilemmas of high-grade transformation (Richter\u2019s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review. Histopathology 69, 1066\u20131076 (2016).","journal-title":"Histopathology"},{"key":"51264_CR18","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"51264_CR19","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont, C. et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J. Clin. Oncol. 41, 2238\u20132247 (2023).","journal-title":"J. Clin. Oncol."},{"key":"51264_CR20","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","volume":"36","author":"PA Thompson","year":"2022","unstructured":"Thompson, P. A. et al. A phase two study of high dose blinatumomab in Richter\u2019s syndrome. Leukemia 36, 2228\u20132232 (2022).","journal-title":"Leukemia"},{"key":"51264_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1182\/blood-2022-158298","volume":"140","author":"AP Kater","year":"2022","unstructured":"Kater, A. P. et al. Subcutaneous Epcoritamab in patients with Richter\u2019s syndrome: early results from Phase 1b\/2 Trial (EPCORE CLL-1). Blood 140, 850\u2013851 (2022).","journal-title":"Blood"},{"key":"51264_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/hon.3163_28","volume":"41","author":"C Carlo-Stella","year":"2023","unstructured":"Carlo-Stella, C. et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation. Hematol. Oncol. 41, 63\u201365 (2023).","journal-title":"Hematol. Oncol."},{"key":"51264_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","volume":"42","author":"R He","year":"2018","unstructured":"He, R. et al. PD-1 Expression in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and potential surrogate marker for clonal relatedness. Am. J. Surg. Pathol. 42, 843\u2013854 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"51264_CR24","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek, M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446\u20135456 (2008).","journal-title":"Blood"},{"key":"51264_CR25","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"51264_CR26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ajh.25956","volume":"95","author":"L Jondreville","year":"2020","unstructured":"Jondreville, L., Krzisch, D., Chapiro, E. & Nguyen-Khac, F. The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. Am. J. Hematol. 95, 1361\u20131367 (2020).","journal-title":"Am. J. Hematol."},{"key":"51264_CR27","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51264-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T15:03:32Z","timestamp":1723215812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51264-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51264"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51264-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G. reports research grants from Amgen, AstraZeneca, Roche, Janssen, Abbvie, and BeiGene; consulting fees; honoraria; and travel funds from AstraZeneca, Roche, Janssen, Abbvie, and BeiGene. J.G. reports consulting fees, honoraria, and travel funds from AstraZeneca, Janssen, Sanofi. E.F. reports consulting fees, honoraria, and travel funds from AstraZeneca, Janssen, Abbvie, and BeiGene. A.C. reports consulting fees, honoraria and travel funds from AstraZeneca, Roche, Janssen, and Abbvie. J.B. reports honoraria from AstraZeneca and Janssen, and travel funds from AstraZeneca and Abbvie. K.L. has received research grants from AbbVie, AstraZeneca, Novartis, BeiGene, Amgen, as well as personal fees from AbbVie, Novartis, BMS, BeiGene, Takeda, Janssen, AstraZeneca, and Amgen. P.F. reports, consulting fees, honoraria, and travel funds from AstraZeneca, Roche, Gilead, Janssen, BeiGene, and Lilly. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6822"}}